Skip to main content

Table 2 Parameters for calculating the NMB

From: Cost-effectiveness modelling to optimise active screening strategy for gambiense human African trypanosomiasis in endemic areas of the Democratic Republic of Congo

Parameter Name Value
WTPc Willingness-to-pay per DALY Varies
G GDP per capita for the DRC1 <DOLLAR/>457.85
D1 Discounted average years of life lost per death 21.03 years
D2 Stage 1 disability weight 0.1330
D3 Stage 2 disability weight 0.5432
C1 Active screening capital cost per person <DOLLAR/>0.22
C2 Active screening recurrent cost per person <DOLLAR/>0.77
C3 Active screening test per person2 <DOLLAR/>1.03
C4 Confirmation per person3 <DOLLAR/>10.96
C5 Stage determination per person in stage 13 <DOLLAR/>1.59
C6 Stage determination per person in stage 23 <DOLLAR/>17.21
C7 Passive screening person in stage 13,4 <DOLLAR/>14.17
C8 Passive screening person in stage 23,4 <DOLLAR/>29.79
C9 Stage 1 treatment per person5 <DOLLAR/>85.23
C10 Stage 2 treatment per person6 <DOLLAR/>561.78
NH Population size Varies
  1. 12018 value used. 2We assume the use of the card agglutination test for trypanosomiasis (CATT) test. 3We assume confirmation is by microscopy using a blood sample, lymph node aspiration (LNA) and mini Anion Exchange Centrifugation Technique (mAECT). 4Passive screening includes the screening test (CATT), outpatient consultation, confirmation and stage determination if appropriate. 5We assume the use of both pentimidine and fexinidazle in proportions described in Additional file 1: Table S4. 6We assume the use of both nifurtimox-eflornithine combination therapy (NECT) and fexinidazole in proportions described in Additional file 1: Table S4
  2. Values are given as the mean value. For more detailed calculations of these cost parameters see Additional file 1